Lysine acetylation in obesity, diabetes and metabolic disease

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 39-46

  Iyer, Abishek ^a   Fairlie, David P ^a   Brown, Lindsay ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

diabetes; HDAC inhibitor; immune; inflammation; metabolic syndrome; obesity

Indexed keywords

ACYLTRANSFERASE; ANTINEOPLASTIC AGENT; ANTIOBESITY AGENT; CYTOKINE; ENZYME INHIBITOR; GLUCOSE; INSULIN; LIPID; LYSINE; LYSINE ACETYLTRANSFERASE; LYSINE DEACETYLASE; LYSINE DEACETYLASE INHIBITOR CLASS I; LYSINE DEACETYLASE INHIBITOR CLASS II; LYSINE DEACETYLASE INHIBITOR CLASS III; LYSINE DEACETYLASE MODULATOR; PANOBINOSTAT; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACETYLATION; ADIPOCYTE; ADIPOSE TISSUE; BLOOD BRAIN BARRIER; BRAIN; CARDIOVASCULAR DISEASE; CELL FUNCTION; DRUG DESIGN; ENERGY CONSERVATION; ENERGY CONSUMPTION; ENZYME ACTIVATION; ENZYME INHIBITION; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; LYSINE ACETYLATION; MACROPHAGE; MAST CELL; METABOLIC BALANCE; METABOLIC DISORDER; METABOLIC REGULATION; MONOCYTE; NEOPLASM; NERVE FIBER; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ACETYLATION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LYSINE; OBESITY;

PROKARYOTA;

EID: 84855454389     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.99     Document Type: Review

References (69)

1. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 2010; 6: 71-82.
2. Iyer A, Brown L. Lipid mediators and inflammation in glucose intolerance and insulin resistance. Drug Discov Today Dis Mech 2010; 7: e191-e197.
3. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867. (Pubitemid 46024993)
4. Van Gaal LF, Mertens IL, De Block CE. Mechanism slink in gobesity with cardiovas cular disease. Nature 2006; 444: 875-880.
5. Iyer A, Kauter K, Brown L. Gender differences in metabolic syndrome a key research issue? Endocr Metab Immune Disord Drug Targets 2011; 11: 182-188.
6. Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA, Diwan V et al. High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. JCardiovasc Pharmacol 2011; 57: 611-624.
7. Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol 2011; 2011: 351982.
8. Patel J, Iyer A, Brown L. Evaluation of the chronic complications of diabetes in a high fructose diet in rats. Indian J Biochem Biophys 2009; 46: 66-72.
9. Iyer A, Panchal S, Poudyal H, Brown L. Potential health benefits of Indian spices in the symptoms of the metabolic syndrome: A review. Indian J Biochem Biophys 2009; 46: 467-481.
10. Horng T, Hotamisligil GS. Linking the inflammasome to obesity-related disease. Nat Med 2011; 17: 164-165.
11. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-445.
12. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009; 49: 123-150.
13. Cui W, Lapointe M, Gauvreau D, Kalant D, Cianflone K. Recombinant C3ades Arg/ acylation stimulating protein (ASP) is highly bioactive: A critical evaluation of C5L2 bindingand 3T3-L1 adipocyteactivation. Mol Immunol 2009; 46: 3207-3217.
14. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 2010; 120: 3466-3479.
15. Red Eagle A, Chawla A. In obesity and weight loss, all roads lead to the mighty macrophage. J Clin Invest 2010; 120: 3437-3440.
16. Norvell A, Mc Mahon SB. Cell biology. Rise of the rival. Science 2010; 327: 964-965.
17. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
18. Weinert BT, Wagner SA, Horn H, Henriksen P, Liu WR, Olsen JV et al. Proteome-wide mapping of the Drosophila acetylome demonstrates a high degree of conservation of lysine acetylation. Sci Signal 2011; 4: ra48.
19. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-840.
20. Halili MA, Andrews MR, Sweet MJ, Fairlie DP Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009; 9: 309-319.
21. Mc Kinsey TA. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med 2011; 17:434-441.
22. Bush EW, Mc Kinsey TA. Targeting histone deacetylases for heart failure. Expert Opin Ther Targets 2009; 13: 767-784.
23. Wang Q, Zhang Y, Yang C, Xiong H, Lin Y, Yao J et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 2010; 327: 1004-1007.
24. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang Tet al. Regulation of cellular metabolism by protein lysineacetylation. Science 2010; 327: 1000-1004.
25. Lam TK. Neuronal regulation of homeostasis by nutrient sensing. Nat Med 2010; 16: 392-395.
26. Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targetingthecorrect HDAC(s) to treat cognitivedisorders. Trends Pharmacol Sci 2010; 31: 605-617.
27. Kazantsev AG, Thompson LM. The rapeutic application of histonedeacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7: 854-868.
28. Schwer B, Schumacher B, Lombard DB, Xiao C, Kurtev MV, Gao J et al. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. Proc Natl Acad Sci USA 2010; 107: 21790-21794.
29. Funato H, Oda S, Yokofujita J, Igarashi H, Kuroda M. Fasting and high-fat diet alter histone deacetylase expression in the medial hypothalamus. PLo S One 2011; 6: e18950.
30. Velasquez DA, Martinez G, Romero A, Vazquez MJ, Boit KD, Dopeso-Reyes IG et al. The central Sirtuin 1/p53 pathway is essential fortheorexigenic action of ghrelin. Diabetes 2011; 60: 1177-1185.
31. Taylor DM, Balabadra U, Xiang Z, Woodman B, Meade S, Amore A et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem Biol 2011; 6: 540-546.
32. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523.
33. Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med 2011; 43: 198-211.
34. Nasrin N, Wu X, Fortier E, Feng Y, Bare OC, Chen S et al. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J Biol Chem 2010; 285: 31995-3 2002.
35. Lagace DC, Nachtigal MW. Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 2004; 279: 18851-18860. (Pubitemid 38623312)
36. Catalioto RM, Maggi CA, Giuliani S. Chemically distinct HDAC inhibitors prevent adipose conversion of subcutaneous human white preadipocytes at an early stage of the differentiation program. Exp Cell Res 2009; 315: 3267-3280.
37. Kim SN, Choi HY, Kim YK. Regulation of adipocyte differentiation by histone deacetylase inhibitors. Arch Pharm Res 2009; 32: 535-541.
38. Haberland M, Carrer M, Mokalled MH, Montgomery RL, Olson EN. Redundant control of adipogenesis by histone deacetylases 1 and 2. J Biol Chem 2010; 285: 14663-14670.
39. Chatterjee TK, Idelman G, Blanco V, Blomkalns AL, Piegore Jr MG,Weintraub DSet al. Histone deacetylase 9 isa negative regulator of adipogenic differentiation. JBiol Chem 2011; 286: 27836-27847.
40. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-776. (Pubitemid 38833129)
41. Jin Q, Zhang F, Yan T, Liu Z, Wang C, Ge X et al. C/EBPalpha regulates SIRT1 expression during adipogenesis. Cell Res 2010; 20: 470-479.
42. Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through Fox O1 acetylation/deacetylation. Cell Metab 2007; 6: 105-114. (Pubitemid 47163621)
43. Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/ enhancer-binding protein alpha transcriptional complex. J Biol Chem 2006; 281: 39915-39924. (Pubitemid 46041795)
44. Yoo EJ, Chung JJ, Choe SS, Kim KH, Kim JB. Down-regulation of histonedeacetylases stimulates adipocyte differentiation. J Biol Chem 2006; 281: 6608-6615.
45. Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN et al. Genetic deficiencyand pharmacological stabilization of mast cells reducediet-induced obesityand diabetes in mice. Nat Med 2009; 15: 940-945.
46. Lumeng CN, Maillard I, Saltiel AR. T-ing up inflammation in fat Nat Med 2009; 15: 846-847.
47. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M et al. CD8+ effector Tcells contribute to macrophage recruitment and adiposetissue inflammation inobesity. Nat Med 2009; 15: 914-920.
48. Lolmede K, Duffaut C,Zakaroff-Girard A, Bouloumie A. Immunecellsinadiposetissue: Key players in metabolic disorders. Diabetes Metab 2011; 37: 283-290.
49. Christensen DP, Dahllof M, Lundh M, Rasmussen DN, Nielsen MD, Billestrup N et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med 2011; 17: 378-390.
50. Susick L, Senanayake T, Veluthakal R, Woster PM, Kowluru A. A novel histone deacetylase inhibitor prevents IL-1beta induced metabolic dysfunction in pancreatic beta-cells. JCell Mol Med 2009; 13: 1877-1885.
51. Lewis EC, Blaabjerg L, Storling J, Ronn SG, Mascagni P, Dinarello CA et al. The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet beta cells in vivo and in vitro. Mol Med 2011; 17: 369-377.
52. Bordone L, Guarente L. Sirtuins and beta-cell function. Diabetes Obes Metab 2007; 9: 23-27.
53. Lee JH, Song MY, Song EK, Kim EK, Moon WS, Han MK et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappa B signaling pathway Diabetes 2009; 58: 344-351.
54. Adcock IM. HDACinhibitorsasanti-inflammatoryagents. Br JPharmacol 2007; 150: 829-831.
55. Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010; 45: 2095-2116.
56. Iyer A, Fenning A, Lim J, Le GT, Reid RC, Halili MA et al. Antifibrotic activity of an inhibitor of histonedeacetylases in DOCA-salt hypertensive rats. Br JPharmacol 2010; 159: 1408-1417.
57. Adcock IM, Tsaprouni L, Bhavsar P, Ito K. Epigenetic regulation of airway inflammation. Curr Opin Immunol 2007; 19: 694-700. (Pubitemid 350236802)
58. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2005; 2: 445-455. (Pubitemid 43879443)
59. Kroon PA, Iyer A, Chunduri P, Chan V, Brown L. Thecardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr Med Chem 2010; 17: 2442-2455.
60. Chan V, Fenning A, Iyer A, Hoey A, Brown L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 2011; 12: 429-436.
61. Aljada A, Dong L, Mousa SA. Sirtuin-targeting drugs: Mechanisms of action and potential The rapeutic applications. Curr Opin Investig Drugs 2010; 11: 1158-1168.
62. Camins A,Sureda FX,Junyent F,Verdaguer E, Folch J, Pelegri Cet al.Sirtuinactivators: designing molecules to extend life span. Biochim Biophys Acta 2010; 1799: 740-749.
63. Chen L. Medicinal chemistry of sirtuin inhibitors. Curr Med Chem 2011; 18: 1936-1946.
64. Kume S, Uzu T, Kashiwagi A, Koya D. SIRT1, a calorie restriction mimetic, in a new therapeutic approach for type 2 diabetes mellitus and diabetic vascular complications. Endocr Metab Immune Disord Drug Targets 2010; 10: 16-24.
65. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol 2009; 5: 367-373.
66. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-196. (Pubitemid 37150899)
67. Lin SJ, Kaeberlein M, Andalis AA, Sturtz LA, Defossez PA, Culotta VC et al. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature 2002; 418: 344-348. (Pubitemid 34790687)
68. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-716. (Pubitemid 350207685)
69. Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, Farley N et al. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci USA 2011; 108:5620-5625.